Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds bacterium or component thereof or substance produced...
Reexamination Certificate
2001-01-26
2004-12-07
Graser, Jennifer E. (Department: 1645)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds bacterium or component thereof or substance produced...
C424S130100, C424S150100, C424S139100, C424S164100, C530S387100, C530S388400
Reexamination Certificate
active
06827935
ABSTRACT:
BACKGROUND OF THE INVENTION
Pseudomonas aeruginosa
is an opportunistic bacterial pathogen that is capable of causing fatal acute lung infections in critically ill individuals (1). The ability of the bacterium to damage the lung epithelium has been linked with the expression of toxins that are directly injected into eukaryotic cells via a type III-mediated secretion and translocation mechanism (2, 3).
The proteins encoded by the
P. aeruginosa
type III secretion and translocation apparatus demonstrate a high level of amino acid identity with members of the Yersinia Yop regulon (4-6). Of all the type III systems discovered in Gram-negative bacteria, only
P. aeruginosa
possesses a homologue to the Yersinia V antigen, PcrV (see 6 for review of type III systems). Homologous proteins to the secretion and translocation apparatus are encoded by both plant and animal pathogenic bacteria. These organisms include human pathogens such as
Salmonella typhimurium, Shigella flexneri
, Enteropathogenic
E. coli
, Chlamydia spp., and plant pathogens such as
Xanthamonas campestris, Pseudomonas syringae, Erwinia amylovora
and
Ralstonia solanacearum
. However, only
P. aeruginosa
and Yersinia encode the V antigen.
Yahr, et al., 1997, discloses the sequence of the operon encoding PcrV and compares the sequence to the LcrV protein. Thus, the amino acid sequence of PcrV is known and is available under accession number AF010149 of GenBank.
SUMMARY OF THE INVENTION
The present invention involves methods and compositions developed from our observation that the Pseudomonas V antigen can be used to protect animals from a lethal lung infection.
In one embodiment, the present invention is a method of inhibiting Pseudomonas infection comprising inoculating a patient with an effective amount of PcrV antigen. In another embodiment, DNA encoding PcrV is used as a gene vaccine.
In one preferred embodiment, the antigen is expressed as a recombinant protein and used to immunize patients at risk.
Preferably, the patient is completely protected from infection.
In another embodiment, the DNA encoding PcrV (called pcrV) or a DNA fragment may be used diagnostically to detect
P. aeruginosa
infection.
In another embodiment, the recombinant protein (rPcrV) is used diagnostically to detect antibodies from patients. Patient antibody response to PcrV may be associated with prognosis. Therefore, in this embodiment the recombinant protein is used as a prognostic indicator by measuring the patient's antibody titer.
The present invention also provides a method for inhibiting a Pseudomonas infection in an individual by contacting the individual with an effective amount of a PcrV inhibitor, in particular with a PcrV antibody, antibody derivative or fragment, or antibody mimic. PcrV antibodies, antibody derivatives and antibody fragments are also provided.
It is an object of the present invention to actively and passively immunize a patient against Pseudomonas infection.
It is another object of the present invention to diagnostically detect the
P. aeruginosa
infection.
It is another object of the present invention to diagnostically detect antibodies from Pseudomonas patients.
Other objects, features and advantages of the present invention will become apparent to one of skill in the art after review of the specification, claims and drawings.
REFERENCES:
patent: 5599665 (1997-02-01), Barbieri et al.
G.W. Anderson, Jr., et al., “Recombinant V Antigen Protects Mice against Pneumonic and Bubonic Plague Caused by F1-Capsule-Positive and -Negative Strains ofYersinia pestis,” Infect. Immun.64(11):4580-4585, 1996.
H. Hahn, et al., “Pilin-Based Anti-Pseudomonas Vaccines: Latest Developments and Perspectives,”Behring Inst. Mitt.98:315-325, 1997.
T. Sawa, et al., “Active and Passive Immunization with thePseudomonasV Antigen Protects against Type III Intoxication and Lung Injury,” Nat. Med. 5(4):392-398, 1999.
T.L. Yahr, et al., “Identification of Type III Secreted Products of thePsuedomonas aeruginosaExoenzyme S Regulon,”J. Bacteriol.179(22):7165-7168, 1997.
Frank Dara W.
Fritz Robert B.
Sawa Teiji
Wiener-Kronish Jeannine
Yahr Timothy L.
Graser Jennifer E.
MCW Research Foundation
Quarles & Brady LLP
LandOfFree
Method of and compositions for immunization with the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of and compositions for immunization with the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of and compositions for immunization with the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3313345